GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » 5-Year Yield-on-Cost %

Nymox Pharmaceutical (Nymox Pharmaceutical) 5-Year Yield-on-Cost % : 0.00 (As of May. 02, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical 5-Year Yield-on-Cost %?

Nymox Pharmaceutical's yield on cost for the quarter that ended in Sep. 2023 was 0.00.


The historical rank and industry rank for Nymox Pharmaceutical's 5-Year Yield-on-Cost % or its related term are showing as below:



NYMXF's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.855
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Nymox Pharmaceutical's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Nymox Pharmaceutical's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's 5-Year Yield-on-Cost % falls into.



Nymox Pharmaceutical 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Nymox Pharmaceutical is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Nymox Pharmaceutical  (OTCPK:NYMXF) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Nymox Pharmaceutical 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical (Nymox Pharmaceutical) Headlines

From GuruFocus

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-22-2022

NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference

By GlobeNewswire GlobeNewswire 11-15-2021

NYMOX Updates Shareholders

By PurpleRose PurpleRose 07-15-2022

Nymox Delisting from NASDAQ

By Marketwired 07-05-2023

NYMOX Appeals Deficiency Letter

By Stock market mentor Stock market mentor 01-06-2023

Nymox Announces Closing of $6.4 Million Financing

By GuruFocusNews GuruFocusNews 04-04-2022

NYMOX Provides Shareholder Update

By Marketwired Marketwired 09-10-2021

Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review

By GlobeNewswire GlobeNewswire 02-15-2023